NCT05405985View on ClinicalTrials.gov

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

PHASE1CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

November 11, 2022

Study Completion Date

December 8, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Nemolizumab

Nemolizumab with Auto-Injector (AI).

DRUG

Nemolizumab

Nemolizumab with Dual-Chamber Syringe (DCS).

Trial Locations (2)

68502

Galderma Investigational Site 7023, Lincoln

85283

Galderma Investigational Site 7024, Tempe

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT05405985 - Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe | Biotech Hunter | Biotech Hunter